Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

587 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Analysis of risk factors for fatal renal complications after allogeneic hematopoietic cell transplantation.
Yanagisawa R, Koyama H, Yakushijin K, Uchida N, Jinguji A, Takeda W, Nishida T, Tanaka M, Eto T, Ohigashi H, Ikegame K, Matsuoka KI, Katayama Y, Kanda Y, Sawa M, Kawakita T, Onizuka M, Fukuda T, Atsuta Y, Shinohara A, Nakasone H. Yanagisawa R, et al. Among authors: ohigashi h. Bone Marrow Transplant. 2024 Mar;59(3):325-333. doi: 10.1038/s41409-023-02172-4. Epub 2023 Dec 16. Bone Marrow Transplant. 2024. PMID: 38104219
MALDI-TOF MS in post-transplant bloodstream infections: reliable identification of causative bacteria in the neutropenic phase.
Kanaya M, Hayashi Y, Hashimoto D, Endo T, Sugita J, Ohigashi H, Hashiguchi J, Matsukawa T, Matsuoka S, Kosugi-Kanaya M, Goto H, Onozawa M, Kahata K, Fujimoto K, Kondo T, Akizawa K, Shibuya H, Shimizu C, Teshima T. Kanaya M, et al. Among authors: ohigashi h. Bone Marrow Transplant. 2017 May;52(5):778-780. doi: 10.1038/bmt.2016.365. Epub 2017 Jan 30. Bone Marrow Transplant. 2017. PMID: 28134922 Clinical Trial. No abstract available.
Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation.
Zhang Z, Hasegawa Y, Hashimoto D, Senjo H, Kikuchi R, Chen X, Yoneda K, Sekiguchi T, Kawase T, Tsuzuki H, Ishio T, Ara T, Ohigashi H, Nakagawa M, Teshima T. Zhang Z, et al. Among authors: ohigashi h. Bone Marrow Transplant. 2022 May;57(5):775-780. doi: 10.1038/s41409-022-01619-4. Epub 2022 Feb 28. Bone Marrow Transplant. 2022. PMID: 35228711 Free article.
Incidence and course of Epstein-Barr virus viremia after allogeneic hematopoietic stem cell transplant for adult-onset systemic chronic active Epstein-Barr virus disease.
Vaswani PPM, Onozawa M, Hasegawa Y, Ohigashi H, Ara T, Matsukawa T, Yasumoto A, Shiratori S, Goto H, Nakagawa M, Kahata K, Endo T, Hashimoto D, Teshima T. Vaswani PPM, et al. Among authors: ohigashi h. Bone Marrow Transplant. 2023 Dec;58(12):1397-1399. doi: 10.1038/s41409-023-02103-3. Epub 2023 Sep 5. Bone Marrow Transplant. 2023. PMID: 37670048 No abstract available.
Effect of graft-versus-host disease on outcomes of HLA-haploidentical peripheral blood transplantation using post-transplant cyclophophamide.
Shimomura Y, Komukai S, Kitamura T, Sobue T, Akahoshi Y, Kanda J, Ohigashi H, Nakamae H, Hiramoto N, Nagafuji K, Tanaka T, Eto T, Ota S, Maruyama Y, Akasaka T, Matsuoka KI, Mori Y, Fukuda T, Atsuta Y, Terakura S. Shimomura Y, et al. Among authors: ohigashi h. Bone Marrow Transplant. 2024 Jan;59(1):66-75. doi: 10.1038/s41409-023-02142-w. Epub 2023 Oct 28. Bone Marrow Transplant. 2024. PMID: 37898725
Hematopoietic stem cell transplantation from haploidentical offspring donors using post-transplant cyclophosphamide versus human leukocyte antigen-matched siblings in older patients with myelodysplastic syndrome.
Shimomura Y, Kitamura T, Konuma T, Nakaya Y, Doki N, Sawa M, Nakamae H, Eto T, Nishida T, Ohigashi H, Ota S, Onizuka M, Hiramoto N, Kawakita T, Kanda J, Ichinohe T, Atsuta Y, Itonaga H. Shimomura Y, et al. Among authors: ohigashi h. Am J Hematol. 2024 Feb;99(2):E42-E45. doi: 10.1002/ajh.27160. Epub 2023 Nov 15. Am J Hematol. 2024. PMID: 37966972 No abstract available.
Low- versus standard-dose post-transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation.
Fuji S, Sugita J, Najima Y, Konishi T, Tanaka T, Ohigashi H, Eto T, Nagafuji K, Hiramoto N, Matsuoka KI, Maruyama Y, Ota S, Ishikawa J, Kawakita T, Akasaka T, Kamimura T, Hino M, Fukuda T, Atsuta Y, Yakushijin K. Fuji S, et al. Among authors: ohigashi h. Br J Haematol. 2024 Mar;204(3):959-966. doi: 10.1111/bjh.19228. Epub 2023 Nov 30. Br J Haematol. 2024. PMID: 38037468
Comparison of Allogeneic Transplant Outcomes Between Matched Sibling Donors and Alternative Donors in Patients Over 50 Years of Age with Acute Myeloid Leukemia: 8/8 Allele-Matched Unrelated Donors and Unrelated Cord Blood Provide Better Leukemia-Free Survival Compared with Matched Sibling Donors During Nonremission Status.
Konuma T, Yamasaki S, Ishiyama K, Mizuno S, Hayashi H, Uchida N, Shimabukuro M, Tanaka M, Kuriyama T, Onizuka M, Ishiwata K, Sawa M, Tanaka T, Ohigashi H, Fujiwara SI, Matsuoka KI, Ota S, Nishida T, Kanda Y, Fukuda T, Atsuta Y, Nakasone H, Yanada M; Adult Acute Myeloid Leukemia and Donor/source Working Groups of the Japanese Society for Transplantation and Cellular Therapy. Konuma T, et al. Among authors: ohigashi h. Transplant Cell Ther. 2024 Feb;30(2):215.e1-215.e18. doi: 10.1016/j.jtct.2023.12.002. Epub 2023 Dec 9. Transplant Cell Ther. 2024. PMID: 38081415
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus HLA-Matched Unrelated Donor Transplantation for Myelodysplastic Syndrome.
Nakaya Y, Koh H, Konuma T, Shimomura Y, Ishiyama K, Itonaga H, Hino M, Doki N, Nishida T, Ohigashi H, Matsuoka KI, Kanda Y, Maruyama Y, Sawa M, Eto T, Hiramoto N, Fukuda T, Atsuta Y, Nakamae H. Nakaya Y, et al. Among authors: ohigashi h. Transplant Cell Ther. 2024 Mar;30(3):316.e1-316.e12. doi: 10.1016/j.jtct.2023.10.021. Epub 2023 Oct 30. Transplant Cell Ther. 2024. PMID: 38108263
Impact of stem cell selection between bone marrow and peripheral blood stem cells for unrelated hematopoietic stem cell transplantation for hematologic malignancies: on behalf of the Donor/Source Working Group of the Japanese Society for Transplantation and Cellular Therapy.
Hayashi H, Iwasaki M, Nakasone H, Tanoshima R, Shimabukuro M, Takeda W, Nishida T, Kako S, Fujiwara SI, Katayama Y, Sawa M, Serizawa K, Matsuoka KI, Uchida N, Ikeda T, Ohigashi H, Fukushima K, Hino M, Kanda Y, Fukuda T, Atsuta Y, Kanda J. Hayashi H, et al. Among authors: ohigashi h. Cytotherapy. 2024 Feb;26(2):178-184. doi: 10.1016/j.jcyt.2023.11.012. Epub 2023 Dec 16. Cytotherapy. 2024. PMID: 38108686
587 results